INTRANASAL INSULIN IMPROVES COGNITION AND MODULATES β-AMYLOID IN EARLY AD

Authors:

Abstract
First, the sample was somewhat heterogeneous—comprising patients with AD but also mild cognitive impairment with amnestic features (aMCI). Some baseline differences were evident in cognition and serologic markers between treatment and placebo. For example, memory savings scores for baseline placebo and treatment, plus 21-day follow-up placebo arms, appeared to be different, but would be expected to be rather similar. Could these differences be related to incomplete randomization, possibly related to small sample size? The proportion of AD and aMCI patients by treatment and placebo groups would be useful to know. Several patients were unable to perform the Stroop Color-Word task or had missing bloodwork. From which groups were these data missing?